home / stock / lixt / lixt news

LIXT News and Press, Lixte Biotechnology Holdings Inc. From 10/09/23

Stock Information
Company Name: Lixte Biotechnology Holdings Inc.
Stock Symbol: LIXT
Market: OTC
Website: lixte.com
Menu
LIXT LIXT Quote LIXT Short LIXT News LIXT Articles LIXT Message Board
Get LIXT Alerts

News, Short Squeeze, Breakout and More Instantly...
LIXT - LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the ...
LIXT - Lixte Biotechnology appoints Bas van der Baan as President, CEO

2023-09-26 10:44:56 ET More on Lixte Biotechnology Holdings Financial information for Lixte Biotechnology Holdings, Inc. For further details see: Lixte Biotechnology appoints Bas van der Baan as President, CEO

LIXT - LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Biotechnology V eteran Bas van der Baan B rings P recision O ncology E xpertise ; Founder John S . Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, I...

LIXT - Atara Biotherapeutics, Butterfly Network among healthcare movers

2023-09-20 10:00:02 ET More on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutive week Wolfe Research stays defensive as it says markets wi...
LIXT - LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( ...

LIXT - LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the closing of its previously announced registered direct offering of 583,334 shares of common stock (or comm...

LIXT - iCAD, Biophytis top healthcare gainers; Lixte, Masimo lead losers pack

2023-07-18 10:13:56 ET Gainers: iCAD ( ICAD ) +31% . Biophytis ( BPTS ) +27% . Hyperfine ( HYPR ) +15% . Cabaletta Bio ( VERU ) +12% . Mind Medicine (MindMed) ( MNMD ) +10% . Losers: Lixte Biotechnology ( LIXT ) ...
LIXT - LITE, NVFY and LIXT among pre-market losers

2023-07-18 08:27:05 ET Masimo Corporation MASI -29% in wake of preliminary Q2 report . CEL-SCI Corporation CVM -19% on pricing $5 million capital raise via stock offering . Lixte Biotechnology Holdings ( LIXT ) -15% announces pricing of $3.5 Million offer...

LIXT - LIXTE Biotechnology falls after company launches $3.5M registered direct offering of shares

2023-07-18 08:23:22 ET LIXTE Biotechnology Holdings ( NASDAQ: LIXT ) fell ~26% Tuesday pre-market after the drug discovery company said it has launched a $3.5M registered direct offering of shares. The company has entered into a securities purchase agreement with a single heal...

LIXT - LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has entered into a securities purchase agreement with a single health-care focused, institutional investor for...
Previous 10 Next 10